Big Molecule Watch
June 9, 2017

Mylan Files Two Petitions for IPR of Sanofi’s Insulin Glargine Patents

Mylan has filed two petitions for inter partes review of Sanofi’s patents related to insulin glargine:  IPR2017-01526 on U.S. Patent 7,476,652, and IPR2017-01528 on U.S. Patent 7,713,930.  Insulin glargine is marketed under the tradename Lantus®.

As we have reported, both the ‘652 and ‘930 patents are the subject of litigation pending in the District of Delaware: Sanofi-Aventis U.S. v. Merck Sharpe and Dohme Corp., No. 16-00812.

These petitions and selected other documents related to IPR of patents related to biologic products are posted on our IPR tracker page.